Inquis Secures $40M to Revolutionize Clot Removal with Aventus Device

Inquis Medical has raised $40 million to support the pivotal trial and planned 2025 launch of Aventus, its newly FDA-cleared thrombectomy system designed for non-surgical blood clot removal. Aventus, unlike its competitors, uses unique sensing technology to inform operators if the device tip is in contact with blood, a clot, or vessel walls, aiming to enhance procedural safety and efficiency. With this funding, Inquis will proceed with its 120-patient trial, targeting improved outcomes for those with acute pulmonary embolism by focusing on reducing blood loss and other procedural inefficiencies.

​

Backed by investment firm Marshall Wace and several existing stakeholders, Inquis aims to set Aventus apart in the competitive thrombectomy market, where innovation is key to patient safety. The company’s novel approach, including the integration of tissue-sensing and blood-return systems, seeks to address the limitations of current devices and provide a safer, more effective option for clot removal.